Calcitonin gene-related peptide (CGRP)-antagonizing drugs represent a major advance in
migraine treatment. However, up to 50% of patients do not benefit from monoclonal …

Migraine is a debilitating neurological disorder that affects about 12% of the population. In
the past decade, the role of the neuropeptide calcitonin gene-related peptide (CGRP) in …

The neuropeptides calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-
activating polypeptide (PACAP) have emerged as mediators of migraine pathogenesis. Both …

With the approval of calcitonin gene-related peptide (CGRP) and CGRP receptor
monoclonal antibodies by the Federal Drug Administration, a new era in the treatment of …

Migraine is a widespread and debilitating neurological condition affecting more than a
billion people worldwide. Thus, more effective migraine therapies are highly needed. In the …

Migraine is a highly prevalent headache disease that typically affects patients during their
most productive years. Despite significant progress in understanding the underlying …

Migraine is a neurovascular disorder that can be debilitating for individuals and society.
Current research focuses on finding effective analgesics and management strategies for …

Introduction: The neuropeptide calcitonin gene-related peptide (CGRP) is recognized as a
critical player in migraine pathophysiology. Excitement has grown regarding CGRP because …

Background Migraine is a disabling and chronic neurovascular headache disorder.
Trigeminal vascular activation and release of calcitonin gene-related peptide (CGRP) play a …

Migraine is a neurological disorder that manifests as a debilitating headache associated
with altered sensory perception. The neuropeptide calcitonin gene-related peptide (CGRP) …